Antitubercular Agent Development and Evaluation

Tuberculosis, caused by Mycobacterium tuberculosis, persists as a global health emergency exacerbated by the rise of multidrug-resistant and extensively drug-resistant strains. Development of new antitubercular agents combines target-based approaches, whole-cell screening and phenotypic assays to identify compounds capable of penetrating the complex, lipid-rich mycobacterial cell envelope and achieving bactericidal activity. Early discovery campaigns frequently employ high-throughput screening against established targets such as cell-wall biosynthetic enzymes, energy-metabolism pathways and redox-active systems. Hits are refined through structure–activity relationship (SAR) studies to balance potency, selectivity and pharmacokinetic properties, while minimising host toxicity. Advances in medicinal chemistry have emphasised the role of physicochemical characteristics—particularly lipophilicity and molecular size—in ensuring adequate uptake and retention within infected macrophages and necrotic granulomas. Lead optimisation integrates in vitro assays, macrophage infection models and in vivo efficacy studies, alongside ADME (absorption, distribution, metabolism and excretion) profiling. Rapid resistance profiling, including selection of resistant mutants and mechanism-of-action elucidation, informs combination regimens designed to forestall escape mutants. The global significance of this work is underscored by ongoing clinical trials of novel scaffolds and repurposed drugs, offering promising avenues to shorten treatment duration and improve outcomes in high-burden settings.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antitubercular Agent Development and Evaluation publication trend

The graph below shows the total number of articles in antitubercular agent development and evaluation across all publications each year (not limited to Nature Index journals).

Technical terms

Minimum Inhibitory Concentration (MIC): lowest concentration of an antimicrobial that prevents visible growth of M. tuberculosis under defined conditions.

Structure–Activity Relationship (SAR): systematic study of how variations in chemical structure affect biological activity, guiding lead optimisation.

Lipophilicity: measure of a compound’s affinity for lipid environments, critical for penetration of the waxy mycobacterial cell wall.

Deazaflavin-dependent nitroreductase activation pathway: enzymatic reduction of nitroaromatic groups in pro-drugs by a bacterial flavin-dependent nitroreductase, generating reactive intermediates that exert antimycobacterial effects.

References

1. Both Nitro Groups Are Essential for High Antitubercular Activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-Dependent Nitroreductase Activation Pathway. Journal of Medicinal Chemistry (2023).
2. Structure–Activity Relationships of Pyrazolo[1,5‑a]pyrimidin-7(4H)‑ones as Antitubercular Agents. ACS Infectious Diseases (2021).
3. Acetylene containing 2-(2-hydrazinyl)thiazole derivatives: design, synthesis, and in vitro and in silico evaluation of antimycobacterial activity against Mycobacterium tuberculosis. RSC Advances (2022).